Press Releases Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Market Closed - Nasdaq Other stock markets 02:00:01 07/05/2024 am IST			5-day change	1st Jan Change
2.62 ^USD	+1.95%		+6.94%	+48.02%

02/05	Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome	CI
09/04	Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	04/05	AQ
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome	02/05	AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	05/04	AQ
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates	20/03	AQ
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19	15/03	AQ
Taysha Gene Therapies : March 2024 Corporate Presentation	08/03	PU
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	02/03	AQ
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome	29/02	AQ
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs	16/02	AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	02/02	AQ
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference	22/01	AQ
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome	10/01	AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	05/01	AQ
Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies	19/12	PR
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients	29/11	AQ
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates	15/11	AQ
Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14	07/11	AQ
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress	24/23/24	AQ
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress	10/23/10	AQ
Purcell & Lefkowitz LLP Is Investigating Taysha Gene Therapies, Inc. (NASDAQ: TSHA) for Potential Breaches of Fiduciary Duty By Its Board of Directors	03/23/03	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Press Releases

Filters